Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 14/20 | 0.58 |
| ▸ | CA2 | P00918 | 14/20 | 0.58 |
| ▸ | CA12 | O43570 | 11/20 | 0.58 |
| ▸ | CA9 | Q16790 | 9/20 | 0.58 |
| ▸ | CA4 | P22748 | 7/20 | 0.58 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6541006 | 0.85 | CA1 (0.55) | CA1CA2CA12CA9CA4 | |
| SCHEMBL597987 | 0.84 | CA1 (0.69) | CA1CA2CA12CA9CA4 | |
| SCHEMBL6540205 | 0.84 | CA1 (0.69) | CA1CA2CA12CA9CA4 | |
| SCHEMBL6541401 | 0.81 | CA1 (0.59) | CA1CA2CA12CA9CA4 | |
| SCHEMBL6539474 | 0.80 | SMN1; SMN2 (0.52) | CA1CA2CA12CA9CA4 | |
| SCHEMBL6541122 | 0.79 | CA1 (0.68) | CA1CA2CA12CA9CA4 | |
| SCHEMBL6805116 | 0.79 | CA1 (0.63) | CA1CA2CA12CA9CA4 | |
| SCHEMBL597986 | 0.79 | CA1 (0.67) | CA1CA2CA12CA9CA4 | |
| SCHEMBL6271452 | 0.78 | CA12 (0.50) | CA1CA2CA12CA9CA4 | |
| SCHEMBL6540208 | 0.78 | MEN1 (0.73) | CA1CA2CA12CA9CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1389185-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002094770-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | BPHL, FANCD2, HRH2 | CA1 4181/4885CA2 2242/4885CA12 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.